gilead sciences inc
Jump to
11 Results Found
  • Gilead prices COVID-19 drug candidate remdesivir at $2,340 per patient Jun 29, 2020 06:23 PM IST

    Gilead prices COVID-19 drug candidate remdesivir at $2,340 per patient

    The price for US private insurance companies will be $520 per vial, the drugmaker said, which equates to $3,120 per patient for a treatment course using 6 vials of remdesivir.

  • Gilead's remdesivir shows promise in COVID-19 study on monkeys Jun 09, 2020 06:52 PM IST

    Gilead's remdesivir shows promise in COVID-19 study on monkeys

    Remdesivir is the first drug to show improvement in COVID-19 in human trials, and its progress in clinical studies is being closely watched as nations look for a treatment for the disease, which has infected more than 7 million people and killed over 400,000.

  • Gilead's next step on coronavirus: inhaled remdesivir, other easier-to-use versions Jun 02, 2020 04:46 PM IST

    Gilead's next step on coronavirus: inhaled remdesivir, other easier-to-use versions

    Remdesivir is the only drug so far that has been shown to help patients with COVID-19, but Gilead and other companies are looking for ways to make it work better.

  • Gilead says remdesivir helped moderate COVID-19 patients improve Jun 01, 2020 06:58 PM IST

    Gilead says remdesivir helped moderate COVID-19 patients improve

    At Day 11, a higher proportion of patients in the 5-day treatment group achieved improvement in clinical status versus the standard of care group, Gilead said.

  • Data on Gilead drug raises hopes in pandemic fight, Fauci calls it 'highly significant' Apr 30, 2020 07:46 AM IST

    Data on Gilead drug raises hopes in pandemic fight, Fauci calls it 'highly significant'

    Preliminary results from a U.S. government trial showing that patients given remdesivir recovered 31% faster than those given a placebo, were hailed by Dr Anthony Fauci as "highly significant."

  • In Pics | All you need to know about Gilead's experimental antiviral drug Remdesivir Apr 29, 2020 09:46 PM IST

    In Pics | All you need to know about Gilead's experimental antiviral drug Remdesivir

    The drug is not yet licensed or approved anywhere globally and has not yet been demonstrated to be safe or effective for the treatment of COVID-19

  • Natco up 4% on settlement with US cos for antiviral drug Dec 14, 2015 09:45 AM IST

    Natco up 4% on settlement with US cos for antiviral drug

    Natco and Alvogen have partnered on the first abbreviated new drug application (ANDA) containing a paragraph IV certification filed with the US Food and Drug Administration (FDA) for generic versions of Tamiflu oral capsules (oseltamivir phosphate), 30 mg, 45 mg and 75 mg.

  • Strides Arcolab launches generic version of Sofosbuvir Mar 27, 2015 09:15 PM IST

    Strides Arcolab launches generic version of Sofosbuvir

    Sofosbuvir has high potency, high barrier to resistance, pan genotypic activity, once-daily dosage, good safety profile and the limited drug-drug interactions, which makes it a breakthrough drug in Hepatitis C treatment.

  • Dr Reddy's to launch Hepatitis C drug in India Mar 23, 2015 06:49 PM IST

    Dr Reddy's to launch Hepatitis C drug in India

    Dr Reddy's Laboratories today entered into an agreement with Hetero to distribute and market generic version of US-firm Gilead Sciences' Hepatitis C drug under the brand 'Resof' in India.

  • Natco Pharma ties up with Gilead on hepatitis C drugs Mar 02, 2015 01:35 PM IST

    Natco Pharma ties up with Gilead on hepatitis C drugs

    Natco will fix its own price for the generic versions, and will pay a royalty on sales to Gilead, the company said.

  • Gilead signs deals with Indian cos for low-cost HIV drug Aug 02, 2012 07:26 PM IST

    Gilead signs deals with Indian cos for low-cost HIV drug

    Gilead Sciences Inc signed deals with three Indian companies to drive sales and reduce manufacturing costs of low-cost generic versions of its HIV drug, Emtricitabine in developing countries.

Sections